Top Markets
Coin of the day
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd.

TARO
Rangering i aksjer #7354
Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven... Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven pharmaceutical enterprise, specializing in the development, manufacturing, and commercialization of both prescription and over-the-counter medications. Its market reach spans the United States, Canada, Israel, and various other international territories. The company also produces active pharmaceutical ingredients (APIs), primarily for integration into its own finished dosage form products. Its extensive product catalog addresses a broad spectrum of medical conditions and therapeutic areas, encompassing treatments for allergies, pain (analgesic), bacterial and fungal infections (antibacterial, antibiotic, antifungal), seizures (anticonvulsant), nausea (antiemetic), inflammation (anti-inflammatory), cancer (anti-cancer, topical anti-neoplastic), blood clot prevention (antiplatelet agent), fever reduction (antipyretic), cardiovascular issues, central nervous system disorders, hormonal regulation (corticosteroid, endocrine), cosmetic applications, coughs and colds, dermatological complaints, fluid management (diuretic), gastrointestinal problems, constipation (laxative), severe pain (narcotics), neuropathic pain, neuropsychiatric conditions, and sleep/anxiety management (sedative/hypnotic). These pharmaceutical goods are available in numerous formats, including capsules, creams, drops, emulsions, gels (and gel kits), granules, injectables, lotions, oils, ointments, pastes, powders (and powders for solution), rectal suppositories, shampoos, solutions (and solutions for infusion), sprays, suspensions, syrups, tablets, toothpastes and mouthwashes, topical foams, and topical solutions. Taro distributes and sells its products directly to a wide array of clients, such as pharmaceutical wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, other direct purchasers, and various healthcare institutions and private pharmacies. The company was established in 1950, with its main offices situated in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a wholly-owned subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
Aksjekurs
$42.98
Sist synkronisert: 2024-06-21
Markedsverdi
$1.62B
Endring (1 dag)
0.01%
Endring (1 år)
0.00%
Land
IL
Handel Taro Pharmaceutical Industries Ltd. (TARO)

Kategori

P/E-forhold for Taro Pharmaceutical Industries Ltd. (TARO)
P/E-forhold per August 2026 TTM: 30.05
Ifølge Taro Pharmaceutical Industries Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 30.05. Ved slutten av 2023 hadde selskapet en P/E på 35.92.
P/E-forholdshistorikk for Taro Pharmaceutical Industries Ltd. fra 1999 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) 30.05 1.98%
2024 29.47 -17.98%
2023 35.92 28.54%
2022 27.95 -497.43%
2021 -7.03 -172.97%
2020 9.64 -36.03%
2019 15.07 -19.08%
2018 18.62 76.40%
2017 10.55 -6.95%
2016 11.34 -9.07%
2015 12.47 -8.53%
2014 13.64 38.57%
2013 9.84 52.53%
2011 6.45 -29.15%
2010 9.11 198.06%
2009 3.06 -69.11%
2008 9.89 27.00%
2007 7.79 -319.39%
2006 -3.55 -104.93%
2005 71.98 -19.62%
2004 89.55 194.34%
2003 30.42 25.42%
2002 24.26 -32.60%
2001 35.99 8.92%
2000 33.04 25.29%
1999 26.38 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.